Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.38 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.38 |
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.38 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.38 |
| ▸ | DUSP5 | Q16690 | 4/20 | 0.55 |
| ▸ | DUSP6 | Q16828 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | PKLR | P30613 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936794 | 0.78 | POLB (0.47) | DUSP5DUSP6PTPN1TDP1PKLR | |
| SCHEMBL312181 | 0.78 | CYP3A4 (0.50) | TDP1CYP3A4TSHRTTRCA1 | |
| SCHEMBL6667051 | 0.78 | CYP3A4 (0.50) | TDP1CYP3A4TSHRTTRCA1 | |
| SCHEMBL3511719 | 0.77 | CA2 (0.64) | DUSP5DUSP6PTPN1TDP1LMNA | |
| SCHEMBL9580693 | 0.76 | CA2 (0.62) | TDP1CYP3A4TSHRTTRCA1 | |
| SCHEMBL1041550 | 0.76 | ING2 (0.52) | TDP1CYP3A4TSHRTTRLMNA | |
| SCHEMBL1005171 | 0.74 | ING2 (0.50) | TDP1CYP3A4TSHRTTRLMNA | |
| SCHEMBL16650007 | 0.74 | CYP3A4 (0.46) | TDP1CYP3A4TSHRTTRCA1 | |
| SCHEMBL124132 | 0.74 | DUSP5 (0.54) | DUSP5DUSP6PTPN1TDP1TSHR | |
| SCHEMBL2919196 | 0.74 | DUSP5 (0.38) | DUSP5DUSP6PTPN1TDP1PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636512-B2 | Esthetic apparatus useful for increasing skin rejuvenation and methods thereof | VENUS CONCEPT INC. (CA) | 2026-05-26 | — | — | US | disclosed |
| US-20260108270-A1 | METHODS AND APPARATUSES FOR SKIN TREATMENT USING NON-THERMAL TISSUE ABLATION | CYTRELLIS BIOSYSTEMS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260096834-A1 | DEVICES AND METHODS FOR COSMETIC SKIN RESURFACING | CYTRELLIS BIOSYSTEMS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260013900-A1 | DEVICES AND METHODS FOR ABLATION OF THE SKIN | CYTRELLIS BIOSYSTEMS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250359887-A1 | SKIN TREATMENT SYSTEMS, DEVICES AND METHODS | CYTRELLIS BIOSYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250359949-A1 | METHOD AND DEVICE FOR TREATING CELLULITE | VENUS CONCEPT INC. (CA) | 2025-11-27 | — | — | US | disclosed |
| US-20250359888-A1 | METHOD AND DEVICE FOR TREATING CELLULITE | VENUS CONCEPT INC. (CA) | 2025-11-27 | — | — | US | disclosed |
| WO-2025096900-A1 | SYNTHETIC NETWORK MATERIALS AND METHODS OF MAKING AND USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250107937-A1 | METHODS AND DEVICES FOR SKIN TIGHTENING | CYTRELLIS BIOSYSTEMS, INC. | 2025-04-03 | — | — | US | disclosed |
| WO-2025064804-A1 | POLYMERIC BIOMATERIALS FOR TISSUE REGENERATION AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20110010817-A1 | Articles of Manufacture Releasing an Active Ingredient | BIOMOD COLLECTION INC. (CA) | 2011-01-20 | — | — | US | disclosed |
| US-20100305209-A1 | Articles of Manufacture Releasing an Active Ingredient | BIOMOD COLLECTION INC. (CA) | 2010-12-02 | — | — | US | disclosed |
| US-20100226947-A1 | ARTICLES OF MANUFACTURE RELEASING AN ACTIVE INGREDIENT | BIOMOD INC. (CA) | 2010-09-09 | — | — | US | disclosed |
| WO-2010077306-A1 | FEMININE UNDERGARMENT | CARLOZZI ANTONELLA F (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152687-A1 | Feminine undergarment | CARLOZZI ANTONELLA F | 2010-06-17 | — | — | US | disclosed |
| WO-2009137074-A9 | COMPOSITIONS AND METHODS FOR TREATING DIABETIC ULCERS | INDIGENE PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010006442-A1 | ARTICLES OF MANUFACTURE RELEASING AN ACTIVE INGREDIENT | BIOMOD INC. (CA) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009137074-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETIC ULCERS | INDIGENE PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090182425-A1 | Sheet or Tubular Structure Consisting of Elastic Biocompatible Material and its Use | CHARITE - UNIVERSITATSMEDIZIN BERLIN (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-2067494-A1 | Sheet or tubular structure consisting of elastic biocompatible material and its use | Charité-Universitätsmedizin Berlin (DE) | 2009-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636512-B2 | Esthetic apparatus useful for increasing skin rejuvenation and methods thereof | MC1R, CUTA, MMP16 | CA1 4522/4885CA2 4394/4885CA12 4022/4885 |
| US-20260096834-A1 | DEVICES AND METHODS FOR COSMETIC SKIN RESURFACING | CUTA, PARG, PLAT | CA1 4862/4885CA2 4730/4885CA12 4389/4885 |
| US-20260013900-A1 | DEVICES AND METHODS FOR ABLATION OF THE SKIN | CUTA, MMP1, KRT18 | CA1 4180/4885CA2 3032/4885CA12 1639/4885 |
| US-20260108270-A1 | METHODS AND APPARATUSES FOR SKIN TREATMENT USING NON-THERMAL TISSUE ABLATION | CUTA, PIEZO1, DSC1 | CA1 4769/4885CA2 4112/4885CA12 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.